ALXP
ALTHX
Market cap55mUSD
Oct 28, Last price
3.45EUR
1D
3.60%
1Q
-16.06%
IPO
-78.03%
Name
Theranexus SA
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
75.34%
Shs. 5Y
—
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
Net income
-3m
CFO
-884k
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Theranexus, a biopharmaceutical enterprise, specializes in the creation of potential medications for ailments affecting the central nervous system. Their primary investigational compound, THN102, is presently undergoing Phase II clinical evaluation for conditions related to sleep and wake cycles. Furthermore, they are developing THN201 to target neurocognitive challenges associated with Alzheimer's disease, and THN101 for the management of neuropathic discomfort. This company commenced operations in 2013 and is situated in Lyon, France.
Key people
Franck Mouthon
Chairman of the Board, Chief Executive Officer
Julien Veys
Chief Business Development Officer · since 2016
Mathieu Charveriat
Chief Scientific Officer, Deputy Chief Executive Officer
Gwenael Hamon
Director - Representative of Kreaxi
Rodolphe Besserve
Independent Director
Dominique Costantini
Independent Director
Headquarters & legal address
60 AVENUE ROCKEFELLER
PEPINIERE LAENNEC BUREAU N 3E NIVEAU 1
LYON 69008
FR
PEPINIERE LAENNEC BUREAU N 3E NIVEAU 1
LYON 69008
FR
Previous name
THERANEXUS
Valuation
Title EUR in thousands, except ratios and share amounts | FY |
|---|---|
| 2025‑12 | |
| Income | |
Revenues | |
Cost of revenue | |
Unusual Expense (Income) | |
NOPBT | |
NOPBT Margin | |
Operating Taxes | |
Tax Rate | |
NOPAT | |
Net income | |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | |
BB yield | |
| Debt | |
Debt current | |
Long-term debt | |
Deferred revenue | |
Other long-term liabilities | |
Net debt | |
| Cash flow | |
Cash from operating activities | |
CAPEX | |
Cash from investing activities | |
Cash from financing activities | |
FCF | |
| Balance | |
Cash | |
Long term investments | |
Excess cash | |
Stockholders' equity | |
Invested Capital | |
ROIC | |
ROCE | |
| EV | |
Common stock shares outstanding | |
Price | |
Market cap | |
EV | |
EBITDA | |
EV/EBITDA | |
Interest | |
Interest/NOPBT | |